A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Perspectives:
To analyse if the change of specific immune response will correlate with clinical effect of
advanced cervix cancer after radio-chemotherapy.
To evaluate the specific immune response throughout monitor the change of the programmed
death-1(PD-1) in CD8 T cell and CD4 T cell and Treg cell in blood at baseline, before first
brachytherapy and before the last brachytherapy in the advanced Cervix Cancer patients.
To use immunohistochemistry (IHC) technique to monitor the change of programmed death-ligand
1 (PD-L1),CD68,CD8,CD4,PD1 and Treg expression in biopsy at baseline, before first
brachytherapy and before the last brachytherapy in the advanced Cervix Cancer patients.
To detect the change of T cell receptor(TCR) repertoire and Tumor mutation burden (TMB) at
baseline, before first brachytherapy and before the last brachytherapy in the advanced Cervix
Cancer patients.